Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer.
Near infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that combines the specificity of antibodies for targeting tumors with the toxicity induced by a sensitive photoabsorber following exposure to NIR light. Most studies of NIR-PIT have been performed in xenograft models of cancer. The purpose of this study was to evaluate the therapeutic effects of NIR-PIT in a transgenic model of spontaneous lung cancer expressing human EGFR (hEGFR-TL). Mice were separated into 3 groups for the following treatments: (1) no treatment (control); (2) 150 μg of photoabsorber, IR700, conjugated to panitumumab, an antibody targeting EGFR [antibody-photoabsorber conjugate (APC)] intravenously (i.v.) only; (3) 150 μg of APC i.v. with NIR light administration. Each treatment was performed every week up to three weeks. MRI was performed 1 day before and 3, 6, 13, 20, 27, and 34 days after first NIR-PIT. The relative volume of lung tumors was calculated from the tumor volume at each MRI time point divided by the initial volume. Steel test for multiple comparisons was used to compare the tumor volume ratio with that of control. Tumor volume ratio was inhibited significantly in the NIR-PIT group compared with control group (P < 0.01 at all time points). In conclusion, NIR-PIT effectively treated a spontaneous lung cancer in a hEGFR-TL transgenic mouse model. MRI successfully monitored the therapeutic effects of NIR-PIT. Mol Cancer Ther; 16(2); 408-14. ©2016 AACR.
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Yuko
Y
Nakamura
Center for Advanced Preclinical Research, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Zoe Weaver
ZW
Ohler
Center for Advanced Preclinical Research, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Deborah
D
Householder
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Tadanobu
T
Nagaya
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Kazuhide
K
Sato
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Shuhei
S
Okuyama
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Fusa
F
Ogata
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Dagane
D
Daar
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Tieu
T
Hoa
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Peter L
PL
Choyke
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. kobayash@mail.nih.gov.
Hisataka
H
Kobayashi
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D007091:Image Processing, Computer-Assisted; D018796:Immunoconjugates / Q000494:pharmacology; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008279:Magnetic Resonance Imaging; D051379:Mice; D008822:Mice, Transgenic; D008856:Microscopy, Fluorescence; D017319:Photosensitizing Agents / Q000494:pharmacology; D010789:Phototherapy / Q000379:methods; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017319:Photosensitizing Agents; D066246:ErbB Receptors